Addition of New High Cost Specialty Drug Revcovi to BIO Case Covered Services

The drug Revcovi has been added to the High Cost Specialty Drug BIO case type reinsured services effective 10/01/2019. Revcovi is an enzyme replacement therapy used to treat Adenosine deaminase severe combined immune deficiency (ADA-SCID). The process for Reinsurance for the drug will be the same as for other Biological/High Cost Specialty Drugs – see the Reinsurance Manual for details.